Tinea Barbae Medication

  • Author: Jacek C Szepietowski, MD, PhD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Jan 23, 2012
 

Medication Summary

The goals of pharmacotherapy are to eradicate the infection, to reduce morbidity, and to prevent complications.[17]

Next

Antifungals

Class Summary

Mechanism of action usually involves inhibiting pathways (enzymes, substrates, transport) necessary for sterol/cell membrane synthesis or altering the permeability of the cell membrane (polyenes) of the fungal cell.

View full drug information

Griseofulvin (Fulvicin P/G, Grifulvin V)

 

Fungistatic activity. Fungal cell division is impaired by interfering with microtubule. Binds to keratin precursor cells. Keratin is gradually replaced by noninfected tissue, which is highly resistant to fungal invasions.

View full drug information

Terbinafine (Lamisil)

 

Member of allylamine family and a fungicidal agent that inhibits ergosterol synthesis via squalene epoxidase, which results in decreased ergosterol level and increased concentration of squalene; leads to cell death.

Use medication until symptoms significantly improve.

View full drug information

Itraconazole (Sporanox)

 

Fungistatic activity. Synthetic triazole antifungal agent that slows fungal cell growth by inhibiting cytochrome P-450-dependent synthesis of ergosterol, a vital component of fungal cell membranes.

View full drug information

Fluconazole (Diflucan)

 

Fungistatic activity. Synthetic oral antifungal (broad-spectrum bistriazole) that selectively inhibits fungal cytochrome P-450 and sterol C-14 alpha-demethylation, which prevents conversion of lanosterol to ergosterol, thereby disrupting cellular membranes.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Jacek C Szepietowski, MD, PhD  Professor, Vice-Head, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University; Director of the Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Poland

Disclosure: Stiefel GSK Company Salary Employment; Orfagen Consulting fee Consulting; Maruho Consulting fee Consulting; Astellas Consulting fee Consulting; Abbott Consulting fee Consulting; Leo Pharma Consulting fee Consulting

Coauthor(s)

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Specialty Editor Board

Franklin Flowers, MD  Chief, Division of Dermatology, Professor, Department of Medicine and Otolaryngology, Affiliate Associate Professor of Pediatrics and Pathology, University of Florida College of Medicine

Franklin Flowers, MD, is a member of the following medical societies: American College of Mohs Micrographic Surgery and Cutaneous Oncology

Disclosure: Nothing to disclose.

Richard P Vinson, MD  Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association

Disclosure: Nothing to disclose.

Paul Krusinski, MD  Director of Dermatology, Fletcher Allen Health Care; Professor, Department of Internal Medicine, University of Vermont College of Medicine

Paul Krusinski, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Joel M Gelfand, MD, MSCE  Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania

Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology

Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous Chief Editor, William D. James, MD, to the development and writing of this article.

References

  1. Beswick SJ, Das S, Lawrence CM, Tan BB. Kerion formation due to Trichophyton rubrum. Br J Dermatol. Nov 1999;141(5):953-4. [Medline].

  2. Gupta G, Burden AD, Roberts DT. Acute suppurative ringworm (kerion) caused by Trichophyton rubrum. Br J Dermatol. Feb 1999;140(2):369-70. [Medline].

  3. Bonifaz A, Ramirez-Tamayo T, Saul A. Tinea barbae (tinea sycosis): experience with nine cases. J Dermatol. Dec 2003;30(12):898-903. [Medline].

  4. Davis DF, Petri WH, Hood AF. Dairy farmer with a rapidly enlarging lip lesion: tinea barbae. Arch Dermatol. Aug 2006;142(8):1059-64. [Medline].

  5. Kiska DL, Cynamon MH. Photo quiz. Tinea barbae caused by Trichophyton verrucosum. Clin Infect Dis. Oct 1997;25(4):805, 871. [Medline].

  6. Maeda M, Nakashima T, Satho M, Yamada T, Kitajima Y. Tinea barbae due to Trichophyton verrucosum. Eur J Dermatol. May-Jun 2002;12(3):272-4. [Medline].

  7. Kick G, Korting HC. Tinea barbae due to Trichophyton mentagrophytes related to persistent child infection. Mycoses. Nov 1998;41(9-10):439-41. [Medline].

  8. Kawada A, Aragane Y, Maeda A, Yudate T, Tezuka T, Hiruma M. Tinea barbae due to Trichophyton rubrum with possible involvement of autoinoculation. Br J Dermatol. May 2000;142(5):1064-5. [Medline].

  9. Szepietowski JC, Bielicka E, Maj J. Inflammatory tinea barbae due to Trichophyton rubrum infection - autoinnoculation from fingernail onychomycosis?. Case Rep Clin Pract Rev. 2002;3:254-6. [Full Text].

  10. Szepietowski JC, Matusiak L. Trichophyon rubrum autoinoculation from infected nails is not such a rare phenomenon. Mycoses. 2008;51:345-346.

  11. Trotha R, Graser Y, Platt J, et al. Tinea barbae caused by a zoophilic strain of Trichophyton interdigitale. Mycoses. Feb 2003;46(1-2):60-3. [Medline].

  12. Ratka P, Slusarczyk E, Sloboda T, Kusmierski W. [Case of tinea barbae profunda caused by Microsporum nanum]. Przegl Dermatol. Sep-Dec 1983;70(5-6):549-52. [Medline].

  13. Kapdagli H, Ozturk G, Dereli T, et al. Candida folliculitis mimicking tinea barbae. Int J Dermatol. Apr 1997;36(4):295-7. [Medline].

  14. Kurita M, Kishimoto S, Kibe Y, Takenaka H, Yasuno H. Candida folliculitis mimicking tinea barbae. Acta Derm Venereol. Mar-Apr 2000;80(2):153-4. [Medline].

  15. Baran W, Szepietowski JC, Schwartz RA. Tinea barbae. Acta Dermatoven APA. 2004;13:91-4. [Full Text].

  16. Tanuma H, Doi M, Nishiyama S, Katsuoka K. A case of tinea barbae successfully treated with terbinafine. Mycoses. Jan-Feb 1998;41(1-2):77-81. [Medline].

  17. Kwasniewska J. Current antifungal agents in dermatology. Postepy Dermatol (Poznan). 1997;14:129-35.

  18. Bihari A, Simon G. Tinea barbae profunda. Borgyogyaszati Venerol Szemle (Budapest). 1998;74:283-6.

  19. Ceburkovas O, Schwartz RA, Janniger CK. Tinea capitis: current concepts. J Dermatol. Mar 2000;27(3):144-8. [Medline].

  20. De Lacerda MH, Caldeira JB, Delfino JP, Nunes FP, Goncalves H, Lobo C. [Sycosis of the beard (tinea barbae). Analysis of 42 cases]. Med Cutan Ibero Lat Am. 1981;9(3):161-78. [Medline].

  21. Foti C, Diaferio A, Daddabbo M, Angelini G. Tinea barbae associated with erythema nodosum in an immunocompetent man. J Eur Acad Dermatol Venereol. May 2001;15(3):250-1. [Medline].

  22. Glaser DA, Riordan AT. Images in clinical medicine. Tinea barbae: man and beast. N Engl J Med. Mar 12 1998;338(11):735. [Medline].

  23. Krajewska-Kulak E, Niczyporuk W, Lukaszuk C, Bartoszewicz M, Roszkowska I, Edyta M. Difficulties in diagnosing and treating tinea in adults at the Department of Dermatology in Bialystok (Poland). Dermatol Nurs. Dec 2003;15(6):527-30, 534. [Medline].

  24. Macura AB. Resistance to antimycotic drugs. Postepy Dermatol (Poznan). 1997;14:137-40.

  25. Michalowski R, Kuczynska L. [Initial experiences with a natamycin-, neomycin-, and hydrocortisone-containing lotion in tinea barbae]. Mykosen. Mar 1984;27(3):153-6. [Medline].

  26. Sander CS, Sander O, Khatib A, Berger T. Tinea barbae spreading to locus minoris resistentiae. Eur J Dermatol. Mar-Apr 2009;19(2):173-4. [Medline].

  27. Soyer HP, Cerroni L. The significance of histopathology in the diagnosis of dermatomycoses. Acta Derm Venerol (Ljubljana). 1992;1:84-7.

 
Previous
Next
 
Inflammatory tinea barbae resulting from Trichophyton mentagrophytesvar granulosuminfection.
Wax model of kerionlike tinea barbae. Courtesy of the Museum of the Department of Dermatology, University of Medicine, Wroclaw, Poland.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.